Geode Capital Management
AQST icon

Geode Capital Management’s Aquestive Therapeutics AQST Stock Holding History

Geode Capital Management’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.9M Buy
2,622,888
+214,697
+9% +$903K ﹤0.01% 2490
2026
Q1 		$10M Buy
2,408,191
+40,099
+2% +$163K ﹤0.01% 2380
2025
Q4 		$15.3M Buy
2,368,092
+280,144
+13% +$1.75M ﹤0.01% 2155
2025
Q3 		$11.7M Buy
2,087,948
+110,947
+6% +$480K ﹤0.01% 2327
2025
Q2 		$6.54M Buy
1,977,001
+276,295
+16% +$793K ﹤0.01% 2592
2025
Q1 		$4.93M Buy
1,700,706
+46,110
+3% +$140K ﹤0.01% 2662
2024
Q4 		$5.89M Sell
1,654,596
-12,919
-0.8% -$59.6K ﹤0.01% 2665
2024
Q3 		$8.31M Buy
1,667,515
+90,543
+6% +$352K ﹤0.01% 2481
2024
Q2 		$4.1M Buy
1,576,972
+1,038,516
+193% +$3.47M ﹤0.01% 2842
2024
Q1 		$2.29M Buy
538,456
+43,554
+9% +$145K ﹤0.01% 3062
2023
Q4 		$1,000K Buy
494,902
+38,337
+8% +$67.7K ﹤0.01% 3359
2023
Q3 		$699K Buy
456,565
+45,588
+11% +$78.4K ﹤0.01% 3473
2023
Q2 		$678K Buy
410,977
+23,402
+6% +$42.3K ﹤0.01% 3511
2023
Q1 		$442K Hold
387,575
– – ﹤0.01% 3687
2022
Q4 		$349K Buy
387,575
+21,676
+6% +$20.4K ﹤0.01% 3834
2022
Q3 		$428K Buy
365,899
+121,537
+50% +$137K ﹤0.01% 3800
2022
Q2 		$156K Sell
244,362
-10,135
-4% -$13.5K ﹤0.01% 4398
2022
Q1 		$664K Buy
254,497
+201
+0.1% +$587 ﹤0.01% 3800
2021
Q4 		$989K Buy
254,296
+34,656
+16% +$174K ﹤0.01% 3729
2021
Q3 		$957K Sell
219,640
-2
-0% -$8 ﹤0.01% 3698
2021
Q2 		$871K Sell
219,642
-135,214
-38% -$540K ﹤0.01% 3678
2021
Q1 		$1.84M Buy
354,856
+41,532
+13% +$221K ﹤0.01% 3287
2020
Q4 		$1.68M Buy
313,324
+37,906
+14% +$227K ﹤0.01% 3170
2020
Q3 		$1.34M Buy
275,418
+4,972
+2% +$32.5K ﹤0.01% 3093
2020
Q2 		$1.31M Buy
270,446
+121,357
+81% +$559K ﹤0.01% 3054
2020
Q1 		$326K Buy
149,089
+61,021
+69% +$232K ﹤0.01% 3402
2019
Q4 		$512K Buy
88,068
+56,226
+177% +$293K ﹤0.01% 3494
2019
Q3 		$101K Sell
31,842
-1,359
-4% -$5.09K ﹤0.01% 3946
2019
Q2 		$139K Sell
33,201
-42,132
-56% -$216K ﹤0.01% 3875
2019
Q1 		$520K Buy
75,333
+31,125
+70% +$218K ﹤0.01% 3426
2018
Q4 		$278K Buy
44,208
+19,310
+78% +$244K ﹤0.01% 3584
2018
Q3 		$435K Buy
+24,898
New +$410K ﹤0.01% 3515

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return

Geode Capital Management's AQST Position: Q2 2026 in Review

Geode Capital Management increased its Aquestive Therapeutics (AQST) stake by 8.9% in Q2 2026, buying an estimated $903K and bringing the position to 2,622,888 shares worth $10.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2490.

Geode Capital Management first reported a position in AQST in Q3 2018 and has held it in 32 quarters since. The position peaked at $15.3M in Q4 2025. 185 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

  • Geode Capital Management held 2,622,888 shares of Aquestive Therapeutics worth $10.9M as of Q2 2026.
  • Geode Capital Management bought 214,697 Aquestive Therapeutics shares in Q2 2026, an estimated $903K.
  • Aquestive Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #2490 holding.
  • Geode Capital Management first reported a position in Aquestive Therapeutics in Q3 2018 and has held it in 32 quarters since.
  • Geode Capital Management's Aquestive Therapeutics position peaked at $15.3M in Q4 2025.
  • 185 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.